cancer

Immunotherapy has revolutionized cancer treatment, yet the drug discovery process to develop new biotherapeutic antibodies remains arduous. However, significant advances in antibody technology such as phage display have enabled fully human antibodies to be developed from animal-free libraries for just about any antigen.

Cancer remains a leading cause of death worldwide. However, as cancer treatments continue to improve and diagnoses happen sooner, more and more patients are experiencing remission. To further increase survival rates and reduce unnecessary treatment, scientists and clinicians are turning to ultra-sensitive molecular analysis to inform treatment decisions and predict and detect relapse.

Bispecific antibodies (bsAbs) are an important addition to the immuno-oncology toolbox. Designed to recognize two distinct epitopes, bsAbs have enhanced binding, specificity, and efficacy compared to current monovalent antibody therapeutics, making them exciting candidates for more targeted cancer treatments. Learn about bsAbs and how our tools can help scientists with their research on therapeutic candidates.

No patient who has survived cancer wants to hear that they’ve relapsed. But hearing it sooner rather than later can dramatically increase the chances of finding a successful, potentially life-saving treatment. Using next-generation sequencing and Droplet Digital PCR, researchers at the University of Uppsala aim to detect relapse by monitoring patient-specific biomarkers. Read about their ongoing clinical study.

Genetic screens are powerful tools for finding genes associated with a particular phenotype. They play an especially important role in cancer research and are leveraged to identify predictive biomarkers that can be used to improve treatment efficacy or trace the progression of genetic alterations that ultimately lead to disease. The HAP1 cancer cell line model and fluorescence-activated cell sorting (FACS) bring efficiency to the development of genetic screens that is making them a force to be reckoned with.

Growth factors are protein signaling molecules that play crucial roles in the regulation of numerous cellular processes such as proliferation, differentiation, and survival. Learn more about the phosphorylation of one such factor, the epidermal growth factor receptor (EGF R).

Frost & Sullivan, a business consulting firm involved in market research and analysis, conducted a thought leadership forum that brought together experts in the field of immuno-oncology. Follow their discussions about the current state of immunotherapies and the key challenges and future approaches to the targeted use of the immune system in cancer treatment.

R-loops are being investigated as potential therapeutic targets for cancer. Find out what they are, how they form, how their formation is controlled by our cells, and, above all, their potential as therapeutic targets.

Cancer is one of the leading causes of death in the world and, due to an aging population, more and more people are diagnosed with cancer every year. Researchers are actively searching for treatment options in the form of potential biomarkers. Long noncoding RNAs (lncRNAs) have piqued the interest of researchers as a relatively new source of therapeutics. Learn more about lncRNAs and see how they can be used in cancer diagnosis and intervention.